OUR STORY
Cancer is part of our lives.
And we choose to fight back.
We have witnessed the weight of uncertainty, the anxiety of
waiting, and the power of a precise answer. We couldn't accept
the status quo when we knew, deep inside, that we could change
it.
Our mission is to broaden access to personalized cancer care. DiaKwant® brings automated biomarker quantification into the laboratory handling the case, where the pathologist reviews the result.
That is why we built DiaDeep — not just another AI company, but a
team of fighters who believe patients deserve better, both now
and in the long run.
“It’s not a sprint, it’s a marathon, and every one of us is
willing to run it — not for ourselves, but for all those fighting
for their lives every day.”Sanae Salhi · CEO & Co-Founder
01
Built with expert pathologists and oncologists
Our models are trained on expert annotations from practicing
pathologists — not crowd-sourced, not synthetic. We co-develop
with the people who use the tools.
02
Clinically relevant, not just technically impressive
We don't just optimize for performance, we optimize for
decisions — the questions clinicians actually face: prognosis,
treatment response and biomarker scoring.
03
Validated on real-world, multi-center cohorts
Our algorithms are evaluated on large, multi-institutional
cohorts, to check reproducibility across labs, scanners and
patient populations.
Behind every claim is evidence that matters. ↗︎
